Redhill Biopharma Ltd, Ramat Gan Price Target Raised to $25.00 (RDHL)
Stock analysts at Roth Capital increased their target price on shares of Redhill Biopharma Ltd, Ramat Gan (NASDAQ:RDHL) from $24.00 to $25.00 in a report issued on Thursday. Roth Capital’s price target points to a potential upside of 74.46% from the company’s current price.
Redhill Biopharma Ltd, Ramat Gan (NASDAQ:RDHL) traded up 14.79% on Thursday, hitting $16.45. The stock had a trading volume of 4,136 shares. Redhill Biopharma Ltd, Ramat Gan has a 52 week low of $9.01 and a 52 week high of $21.00. The stock’s 50-day moving average is $14.18 and its 200-day moving average is $15.00. The company’s market cap is $144.0 million.
Redhill Biopharma Ltd, Ramat Gan (NASDAQ:RDHL) last posted its quarterly earnings results on Thursday, July 24th. The company reported ($0.52) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.38) by $0.14. On average, analysts predict that Redhill Biopharma Ltd, Ramat Gan will post $-1.35 earnings per share for the current fiscal year.
Redhill Biopharma Ltd is an Israel-based company, engaged in the development of late clinical-stage new, improved, and patented formulations of existing drugs.
Receive News & Ratings for Redhill Biopharma Ltd Ramat Gan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma Ltd Ramat Gan and related companies with Analyst Ratings Network's FREE daily email newsletter.